Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LX
Post# of 721
(Total Views: 230)
Posted On: 07/02/2019 4:24:26 PM
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced DehydraTECH Delivers More CBD into the Body
- The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets
- DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations
- Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than standard industry formulations. These results were confirmed in clinical lab tests conducted with live animals. LXRP has filed new patent applications based on these innovations (http://nnw.fm/bXV3l).
The new DehydraTECH delivery platform is ideally suited for solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical, medical and supplement markets.
LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees.
In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137 percent more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://nnw.fm/SU1sL). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.
In animal tests conducted in 2018 and 2019, results showed that DehydraTECH greatly assisted in the delivery of drugs, including nicotine and cannabinoids, across the blood-brain barrier. The demonstrated effectiveness of DehydraTECH, combined with nanoemulsification, significantly expands the application of the technology for conventional dosage forms, consumable liquids and beverage dosage forms.
LXRP is a Canadian bioscience company and a drug-delivery platform innovator. The company out-licenses its disruptive delivery technology, DehydraTECH. The technology is designed to promote healthier ingestion methods and lower overall dosing. Lexaria is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and has multiple patents pending in more than 40 countries worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets
- DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations
- Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than standard industry formulations. These results were confirmed in clinical lab tests conducted with live animals. LXRP has filed new patent applications based on these innovations (http://nnw.fm/bXV3l).
The new DehydraTECH delivery platform is ideally suited for solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical, medical and supplement markets.
LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees.
In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137 percent more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://nnw.fm/SU1sL). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.
In animal tests conducted in 2018 and 2019, results showed that DehydraTECH greatly assisted in the delivery of drugs, including nicotine and cannabinoids, across the blood-brain barrier. The demonstrated effectiveness of DehydraTECH, combined with nanoemulsification, significantly expands the application of the technology for conventional dosage forms, consumable liquids and beverage dosage forms.
LXRP is a Canadian bioscience company and a drug-delivery platform innovator. The company out-licenses its disruptive delivery technology, DehydraTECH. The technology is designed to promote healthier ingestion methods and lower overall dosing. Lexaria is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and has multiple patents pending in more than 40 countries worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)